Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3760/cma.j.cn112151-20220921-00796 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Renal limited sarcoidosis presenting with acute kidney injury.
Med J Armed Forces India
July 2023
Resident (Nephrology), Army Hospital (R&R), Delhi Cantt, India.
Sarcoidosis is a multisystem granulomatous disease of unknown etiology, characterized by noncaseating epithelioid granuloma, multinucleate giant cells, and tissue destruction. While lung and lymph node involvement is common, isolated renal involvement is rare. We report the case of a 55-year-old female patient, with renal limited sarcoidosis, who presented with worsening sensorium and acute kidney injury.
View Article and Find Full Text PDFSarcoidosis as an Uncommon Cause of Chest Pain: A Case Report.
Cureus
January 2025
Internal Medicine, Hospital Senhora da Oliveira, Guimarães, PRT.
Sarcoidosis is a multisystem granulomatous disease of unknown etiology. Despite primarily affecting the lung, sarcoidosis can affect any organ, resulting in various clinical manifestations. We present a case of a 56-year-old man who developed thoracic pain over several months along with skin lesions.
View Article and Find Full Text PDFCryoablation for airway stenosis caused by malignant pulmonary epithelioid hemangioendothelioma: a case report.
AME Case Rep
November 2024
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Background: Pulmonary epithelioid hemangioendothelioma (P-EHE) is a rare vascular tumor derived from mesenchymal cells with an incidence of about 1/1 million. The etiology remains unclear, and there are no established treatment guidelines. The tumor can occur in a variety of organs, among which the liver, lung and bone are the most commonly involved, with different clinical manifestations, mainly depending on the organ involved, but none of them is specific.
View Article and Find Full Text PDFThe Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis.
Medicina (Kaunas)
January 2025
Medical Oncology, Department of Internal Medicine, Marmara University Faculty of Medicine, İstanbul 34854, Turkey.
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with a poor prognosis. Identifying reliable prognostic factors is crucial for risk stratification and optimizing treatment strategies. This study aimed to evaluate the impact of clinicopathologic factors and systemic inflammatory markers on survival outcomes in patients with MPM.
View Article and Find Full Text PDFFollow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study-FLORA.
ESMO Open
January 2025
Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pulmonary Medicine, Leiden University Medical Center, Leiden, The Netherlands. Electronic address:
Background: Diffuse pleural mesothelioma (dPM) is an aggressive malignancy, primarily treated with palliative systemic therapy. Since 2022, nivolumab-ipilimumab (nivo/ipi) has replaced chemotherapy as the standard first-line treatment for dPM in the Netherlands. Chemotherapy remains a rational second-line treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!